RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy

  • Jinho Yoon
  • , Minkyu Shin
  • , Ji Young Lee
  • , Sang Nam Lee
  • , Jin Ha Choi*
  • , Jeong Woo Choi
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

RNA interference (RNAi) is being extensively investigated as a potential therapeutic strategy for cancer treatment. However, RNAi-based therapeutics have not yet been used to treat cancer because of their instability and the difficulty of microRNA (miRNA) delivery. Plasmonic nanoparticle-based RNAi nanotherapeutics have been developed for accurate and sensitive diagnosis and a strong therapeutic effect on cancers by leveraging their ease-of-use and specific properties such as photothermal conversion. In this review, recent strategies and advances in plasmonic nanoparticle-based miRNA delivery are briefly presented to facilitate the detection and treatment of several cancers. The challenges and potential opportunities afforded by the RNAi-based theragnosis field are discussed. We expect that the RNAi-integrated plasmonic nanotherapeutics discussed in this review can provide insights for the early diagnosis and effective treatment of cancer.

Original languageEnglish
Pages (from-to)228-240
Number of pages13
JournalJournal of Controlled Release
Volume342
DOIs
StatePublished - 2022.02

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • microRNA (miRNA)
  • Nanobiosensor
  • Photothermal therapy
  • Plasmonic nanoparticle
  • RNA interference (RNAi)
  • Small interference RNA (siRNA)
  • Theragnosis

Quacquarelli Symonds(QS) Subject Topics

  • Pharmacy & Pharmacology

Fingerprint

Dive into the research topics of 'RNA interference (RNAi)-based plasmonic nanomaterials for cancer diagnosis and therapy'. Together they form a unique fingerprint.

Cite this